Another woman has joined her complaint to a larger Taxotere MDL claiming that Sanofi Aventis made false claims about Taxotere, the chemotherapy drug she took for treatment.

Plaintiff Annette V., a resident of the state of Georgia, has filed a claim against drugmaker Sanofi Aventis, the manufacturer of chemotherapy drug Taxotere. She, along with all the other plaintiffs in the multidistrict litigation, or MDL, allege that the makers of Taxotere made false claims about Taxotere and that the company did not do enough to warn patients about long-term hair loss.

Taxotere has been associated with long-term hair loss, or alopecia. Most patients who undergo chemotherapy have hair loss of some sort. It is expected during this stage of treatment. However, most patients experience hair regrowth shortly after chemotherapy treatment ceases.

But in the case of Taxotere use, many patients are not fortunate enough to have their hair grow back.

Annette claims that she underwent Taxotere chemotherapy treatment in 2003 in the state of New Jersey.

According to her complaint, Annette holds Sanofi Aventis responsible for her “severe and personal injuries that are permanent and lasting in nature including economic and non-economic damages, harms, losses, including, but not limited to past and future medical expenses, psychological counseling and therapy expenses.”

She also claims that her damages include past and future loss of earnings, past and future loss of earning capacity, permanent disfigurement which includes permanent alopecia. She alleges that Sanofi Aventis made false claims about Taxotere and hair regrowth and did not adequately represent how many patients reported permanent hair loss.

Annette also claims to have suffered mental anguish, severe and debilitating emotional distress, increased risk of future harm, and past, present and future physical and mental pain and suffering.

Taxotere, like other chemotherapy drugs, affects the quickly growing cells of the body. This is how it can wipe out the quickly replicating cells of cancer. But it also attacks hair cells as well.

It was approved in 1996 as a chemotherapy treatment drug, but in the years since, many plaintiffs of various lawsuits have held Sanofi Aventis responsible for making false claims about Taxotere and its superiority to other chemotherapy treatment drugs.

Many lawsuits allege that while Taxotere is more potent and potentially toxic, it is not more effective in treating cancer. In fact, it has permanent and disfiguring side effects that other chemotherapy drugs do not have.

Some studies even claim that up to 10% of Taxotere users report permanent hair loss due to Taxotere use. Taxotere users were not warned until 2015 that they may experience permanent hair loss as a result of their chemotherapy drug.

Because of the false claims about Taxotere that Sanofi Aventis allegedly made, many women have chosen this drug believing it would work better than other drugs. Instead, they have experienced greater side effects than they would have with a different drug.

This False Claims About Taxotere lawsuit is Case No. 2:17-cv-10474-KDE—MBN in the United States District Court of the Eastern District of Louisiana.